Cue Biopharma (NASDAQ:CUE) Stock Price Up 19.9% – What’s Next?

Cue Biopharma, Inc. (NASDAQ:CUE) shares were up 19.9% during mid-day trading on Monday . The stock traded as high as $30.75 and last traded at $30.43. 163,488 shares changed hands during mid-day trading, an increase of 112% from the average session volume of 76,983 shares. The stock had previously closed at $25.39.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Weiss Ratings raised shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen raised shares of Cue Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma presently has an average rating of “Sell”.

Cue Biopharma Price Performance

The stock’s 50-day moving average price is $71.85 and its 200 day moving average price is $213.26. The firm has a market cap of $127.81 million, a P/E ratio of -5.45 and a beta of 2.51.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.30) by $2.22. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The business had revenue of $5.69 million during the quarter, compared to the consensus estimate of $2.50 million.

Institutional Trading of Cue Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Boothbay Fund Management LLC acquired a new position in Cue Biopharma during the third quarter valued at approximately $439,000. Stifel Financial Corp increased its position in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Cue Biopharma during the 3rd quarter worth approximately $62,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc raised its stake in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.